Effectiveness claims in Rx drug ads must state specific approved indications

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

When a prescription drug advertisement claims effectiveness, it must specify the particular approved indications (e.g., specific infection/organism types) for which the drug is claimed effective, as specific as required or permitted in labeling.

Check

For any broad effectiveness claim in a prescription drug advertisement, confirm the ad names the specific indication(s)/conditions consistent with labeling rather than a vague general claim.

Escalate when

Specificity of the claim versus labeling is debatable, or it is unclear whether the piece qualifies as a prescription drug advertisement under 21 CFR 202.1 (as opposed to OTC labeling/advertising or non-advertising promotional material).

Where this comes from

21 CFR 202.1(e)(3)(ii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…sewhere in the advertisement of a more complete discussion of such qualification or information. (ii) The information relating to effectiveness is not required to include information relating to all purposes for which the drug is intended but may optionally be limited to a true statement of the effectiveness of the drug for the selected purpose(s) for which the drug is recommended or suggested in the advertisement. The information relating to effectiveness shall include specific indications for use of the drug for purposes claimed in the advertisement; for example, when an advertisement contains a broad claim that a drug is an antibacterial agent, the advertisement shall name a type or types of infections and microorganisms for which the drug is effective clinically as specifically as required, approved, or permitted in the drug package labeling. (iii) The information relating to side effects and contraindications shall disclose each specific side effect and con…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Material typeprescription-drug-advertisement

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is operative regulatory text in 21 CFR 202.1(e)(3)(ii) using 'shall', not an example, definition, or preamble summary. The illustrative antibacterial clause that follows in the same paragraph ('the advertisement shall name a type or types of infections and microorganisms for which the drug is effective clinically as specifically as required, approved, or permitted in the drug package labeling') directly licenses both the infection/organism parenthetical and the 'as specific as required or permitted in labeling' calibration in the rule statement.
- No conflict with the preceding sentence of (e)(3)(ii), which allows effectiveness information to be limited to selected purposes; the rule demands specificity only for the purposes actually claimed, which matches the source.
- Atomic: a single checkable requirement (name specific indications at labeling-level specificity for the effectiveness claim made).
- Determinism correctly 'judgment': whether a claim is 'broad' and whether the named indications are as specific as labeling requires/permits is a matter of comparison and degree, not a literal match or presence/absence test.
- Authority correctly 'binding': 21 CFR is regulation, and the text is mandatory ('shall').
- Locator correct: the quoted sentence appears verbatim in paragraph (e)(3)(ii) of the source text.
- Severity 'blocker' is defensible: failure to state specific indications defeats the section 502(n) 'true statement' requirement and creates misbranding exposure.
- Overstated on scope: 21 CFR 202.1 governs prescription drug advertisements, and (e)(3)(ii) sits within paragraph (e) whose trigger in (e)(1) is 'All advertisements for any prescription drug, except advertisements described in paragraph (e)(2)'. The rule is scoped only to 'promotional', so as written it reaches OTC materials and non-advertising promotional pieces that this section does not govern. The prescription-drug-advertisement limit appears nowhere in the rule statement, check, or applies_when.
- The (e)(2) reminder-advertisement exemption does not need a separate carve-out, since a reminder ad by definition contains no indications or effectiveness claim and the rule's own trigger ('when an ad claims effectiveness') already excludes it.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quoted sentence is the operative mandate in 21 CFR 202.1(e)(3)(ii) — 'The information relating to effectiveness shall include specific indications for use of the drug for purposes claimed in the advertisement' — not a definition, preamble, or exemption. The rule's parenthetical about infection/organism types is drawn from the regulation's own illustrative 'for example' clause ('the advertisement shall name a type or types of infections and microorganisms... as specifically as required, approved, or permitted in the drug package labeling') and is correctly presented as an example rather than as an independent requirement.
- Not overstated: the source uses 'shall', and the rule states a mandatory obligation of equivalent scope. The rule does not contradict the preceding sentence of (e)(3)(ii), which permits limiting effectiveness information to the selected purposes claimed — the rule is expressly keyed to 'purposes claimed'. Rule text tracks the source's 'as specific as required or permitted in labeling' (dropping 'approved' is immaterial since the rule elsewhere says 'approved indications').
- Atomic: one checkable obligation — specificity of indication(s) accompanying an effectiveness claim. It does not bundle in the fair-balance, brief-summary, or side-effect-disclosure requirements of (e)(3)(iii), (e)(5), or (e)(6).
- Determinism 'judgment' is correct: whether a named indication is 'as specific as' labeling requires turns on comparative adequacy, not on presence/absence of a literal string.
- Authority 'binding' is correct — this is a codified FDA regulation, and the locator 21 CFR 202.1(e)(3)(ii) matches the paragraph containing the quote exactly.
- applies_when is justified and appropriately limited: 202.1(e) applies to prescription drug advertisements, which is the stated material type, and the rule's trigger ('when an advertisement claims effectiveness') naturally excludes the (e)(2) exempt categories — reminder ads (no indications), bulk-sale and compounding ads (no therapeutic effectiveness claims). No invented condition.
- Severity 'blocker' is defensible: failure to satisfy (e)(3) goes to the true-statement requirement under section 502(n) and renders the advertisement violative, so it is not a wording-level defect.
- Minor, non-blocking note: the check narrows to 'broad effectiveness claim' while the regulation's mandate attaches to effectiveness information generally; the example clause concerns broad claims, so the check is conservative rather than overreaching.